Development programme

DURATION — exenatide extended release

The programme for the extended-release once-weekly presentation of exenatide.

Sponsor class: Manufacturer-sponsored. First record: 2007.

Filter by text

Phase

Status

Showing 0 records on this page

Records in this programme

12 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

Record	Compound	Phase	Status	Design	Randomised	Year	Certainty
DURATION-1	Exenatide	Phase 3	Reported	Randomised, open-label, active-controlled	295	2008	High
DURATION-6	Exenatide	Phase 3	Reported	Randomised, open-label, active-controlled	911	2013	High
DURATION-1-ADHERENCEprogramme record	Exenatide	Phase 3	Reported	Observational	—	2008	Very low
DURATION-1-BIOMARKERprogramme record	Exenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2008	Very low
DURATION-1-ELDERLYprogramme record	Exenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2008	Very low
DURATION-1-HEPATIC-IMPprogramme record	Exenatide	Phase 1	Reported	Phase 1 ascending dose	—	2008	Very low
DURATION-1-OLEprogramme record	Exenatide	Phase 3	Reported	Single-arm open-label	—	2008	Very low
DURATION-6-ADHERENCEprogramme record	Exenatide	Phase 3	Reported	Observational	—	2013	Very low
DURATION-6-BIOMARKERprogramme record	Exenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2013	Very low
DURATION-6-ELDERLYprogramme record	Exenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2013	Very low
DURATION-6-OLEprogramme record	Exenatide	Phase 3	Reported	Single-arm open-label	—	2013	Very low
DURATION-6-REGIONAL-JPprogramme record	Exenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2013	Very low